Yusuke Oji
Overview
Explore the profile of Yusuke Oji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berneman Z, De Laere M, Germonpre P, Huizing M, Willemen Y, Lion E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):9.
PMID: 39849594
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant...
2.
Morimoto S, Tanaka Y, Nakata J, Fujiki F, Hasegawa K, Nakajima H, et al.
Cancer Immunol Immunother
. 2024 Nov;
74(1):15.
PMID: 39509060
Wilms' tumor protein 1 (WT1)-targeted immunotherapy has been used in patients with leukemia and solid tumors. However, the spontaneous WT1-specific immune response before WT1 peptide vaccination in patients with WT1-expressing...
3.
Oji Y
Methods Mol Biol
. 2024 Jul;
2821:217-223.
PMID: 38997492
Antibodies serve as crucial indicators of the immune system in clinical tests. In therapeutic cancer vaccines, IgG antibodies against target antigens are vital for immune monitoring. Additionally, assessing baseline antigen-specific...
4.
Fujiki F, Morimoto S, Nishida Y, Tanii S, Aoyama N, Inatome M, et al.
Cancer Immunol Immunother
. 2023 Mar;
72(7):2347-2356.
PMID: 36939853
CD4 T cells that recognize antigenic peptides presented on HLA class II are essential for inducing an optimal anti-tumor immune response, and adoptive transfer of tumor antigen-specific TCR-transduced CD4 T...
5.
Oji Y, Kagawa N, Arita H, Naka N, Hamada K, Outani H, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672344
No standard treatment has been established for most rare cancers. Here, we report a clinical trial of a biweekly WT1 tri-peptide-based vaccine for recurrent or advanced rare cancers. Due to...
6.
Fujiki F, Morimoto S, Katsuhara A, Okuda A, Ogawa S, Ueda E, et al.
Front Immunol
. 2022 Jul;
13:935465.
PMID: 35844620
Memory T cells play an essential role in infectious and tumor immunity. Vitamin A metabolites such as retinoic acid are immune modulators, but the role of vitamin A metabolism in...
7.
Ito M, Oji Y, Adachi M, Imanishi R, Alzaaqi S, Hiwasa T, et al.
Mol Clin Oncol
. 2022 Mar;
16(3):74.
PMID: 35251625
The Wilms tumor 1 gene, , is overexpressed in various types of cancer, including gastric cancer. The product of is highly immunogenic and is a promising target molecule for cancer...
8.
Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, et al.
Sci Transl Med
. 2022 Feb;
14(632):eaax7706.
PMID: 35171652
Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)-based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by an...
9.
Alzaaqi S, Naka N, Hamada K, Hosen N, Kanegae M, Outani H, et al.
Oncol Lett
. 2022 Jan;
23(2):65.
PMID: 35069874
The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL...
10.
Nishida S, Morimoto S, Oji Y, Morita S, Shirakata T, Enomoto T, et al.
J Immunother
. 2021 Dec;
45(1):56-66.
PMID: 34874330
The HLA-A*24:02-restricted peptide vaccine targeting Wilms' tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patients. In this study, we analyzed...